Advertisement

Pfizer says data from late-stage trial shows COVID-19 vaccine 90% effective

By
Don Jacobson
A ticker outside at the New York Stock Exchange shows shares of Pfizer up in early trading on Monday on news that data from its coronavirus vaccine shows it is more than 90% effective. Photo by John Angelillo/UPI
A ticker outside at the New York Stock Exchange shows shares of Pfizer up in early trading on Monday on news that data from its coronavirus vaccine shows it is more than 90% effective. Photo by John Angelillo/UPI | License Photo

Nov. 9 (UPI) -- Drugmaker Pfizer and partner BioNTech announced Monday that tests of their COVID-19 vaccine has shown the first scientific evidence that it can block the coronavirus disease in about 90% of humans.

The results of the companies' late-stage clinical trial showed that just 10% of almost 100 test subjects who tested positive for COVID-19 had received the vaccine rather than a placebo, according to what the firms said was an interim analysis of its third-stage trial.

Advertisement

The companies said their two-dose vaccine provided protection beginning seven days after the second dose and 28 days after the initial dose of the vaccine.

The companies said they will seek emergency use authorization from the Food and Drug Administration "soon after the required safety milestone is achieved," which it now expects as soon as next week.

RELATED Quest for COVID-19 vaccines: Where they stand

"Today is a great day for science and humanity," Pfizer Chairman and CEO Dr. Albert Bourla said in a statement. "The first set of results from our Phase 3 COVID-19 vaccine trial provides the initial evidence of our vaccine's ability to prevent COVID-19."

"The first interim analysis of our global Phase 3 study provides evidence that a vaccine may effectively prevent COVID-19," added BioNTech CEO Ugur Sahin. "This is a victory for innovation, science and a global collaborative effort."

Advertisement

Pfizer and BioNTech have enrolled more than 43,000 volunteers in the third and final stage study, which began in late July. They said nearly 39,000 human subjects have received both doses.

RELATED AstraZeneca COVID-19 vaccine results to be delivered by end of 2020

Sahin said the trial will continue to collect data with goal of a examining the results after 164 confirmed COVID-19 cases have been accrued among participants.

The Pfizer-BioNTech vaccine is one of several candidates now in late-stage clinical trials worldwide, along with candidates being developed by AstraZeneca, Johnson & Johnson, Novavax and Moderna.

RELATED Biden names 13 members of COVID-19 advisory task force

Latest Headlines